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Synapse formation is considered to be crucial for learning and memory. Understanding the underlying molecular mechanisms of
synapseformationisakeytounderstandinglearningandmemory.Kalirin-7,amajorisoformofKalirininadultrodentbrain,isan
essential component of mature excitatory synapses. Kalirin-7 interacts with multiple PDZ-domain-containing proteins including
PSD95, spinophilin, and GluR1 through its PDZ-binding motif. In cultured hippocampal/cortical neurons, overexpression of
Kalirin-7 increases spine density and spine size whereas reduction of endogenous Kalirin-7 expression decreases synapse number,
and spine density. In Kalirin-7 knockout mice, spine length, synapse number, and postsynaptic density (PSD) size are decreased in
hippocampal CA1 pyramidal neurons; these morphological alterations are accompanied by a deﬁciency in long-term potentiation
(LTP) and a decreased spontaneous excitatory postsynaptic current (sEPSC) frequency. Human Kalirin-7, also known as Duo
or Huntingtin-associated protein-interacting protein (HAPIP), is equivalent to rat Kalirin-7. Recent studies show that Kalirin is
relevant to many human diseases such as Huntington’s Disease, Alzheimer’s Disease, ischemic stroke, schizophrenia, depression,
and cocaine addiction. This paper summarizes our recent understanding of Kalirin function.
1. KalirinIsa Rho GuanineNucleotide
Exchange Factor (GEF)
Kalirin was discovered 15 years ago as a novel protein
that interacts with the cytosolic carboxyl-terminal of pep-
tidylglycine α-amidating monooxygenase (PAM), an inte-
gral membrane peptide processing enzyme [1]. We have
made signiﬁcant progress in understanding the functions of
Kalirin; like the many other Rho-GEFs encoded in mam-
malian genomes, Kalirin promotes the exchange of GDP for
GTP and thus stimulates the activity of speciﬁc Rho GTPases
[2, 3]. Rho GTPases that regulate multiple cellular processes
play a key role in transducing signals from extracellular
stimulitotheintracellularpathwaysthatplayapivotalrolein
the formation of dendritic spines and synaptic development
[4–6].
2. Multiple Kalirin Isoforms
The mouse Kalirin gene (Kalrn) consists of 65 exons
spanning >650kb of the genome; the presence of multiple
promoters and transcriptional start sites enables the pro-
duction of multiple functional isoforms of Kalirin [7–9].
Each Kalirin isoform is composed of a unique collection
of domains (Figure 1). Major Kalirin isoforms including
Kalirin-7, -9, and -12 are generated through the use of
alternative 3  exons [8]. The major isoforms share some
common features including nine spectrin-like repeats, the
GEF1 domain and the Sec14p domain. Sec14p domains
facilitate lipid interactions and cellular localization. The nine
spectrin-like repeat regions that follow the Sec14p domain
have been shown to interact with many proteins including
disrupted in schizophrenia 1 (DISC1) [10], peptidylglycine
α-amidating monooxygenase (PAM) [1], inducible nitric
oxide synthase (iNOS) [11], Huntingtin-associated pro-
tein 1 (HAP1) [12], and Arf6 (ADP-ribosylation factor
6) [13]. Kalirin-12 is the longest isoform and contains
additional domains that include GEF2, an immunoglobulin-
like (Ig) domain, a ﬁbronectin III (FnIII) domain, and a
serine/threonine protein kinase domain that is followed by a
short, unique carboxyl-terminus [7, 14]. Kalirin-12 is found2 Neural Plasticity
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Figure 1: Major Kalirin isoforms. Alternative splicing generates diﬀerent isoforms of Kalirin. DH: Dbl homology; PH: pleckstrin homology;
GEF1: guanine nucleotide exchange factor 1; SH3: Src homology domain; GEF2: guanine nucleotide exchange factor 2; I: immunoglobulin-
like; F: ﬁbronectin III-like; Kin: kinase domain; red lines, unique 5 - and 3 -untranslated regions.
in the growth cones of immature neurons (Figure 2)a n d
dendritic spines of mature cultured hippocampal neurons,
suggesting a role for Kalirin-12 in axon outgrowth and
synaptic plasticity. Interaction of the Ig-FnIII region unique
to Kalirin-12 with the GTPase domain of dynamin may
facilitate the coordination of endocytic traﬃcking and
changes in the actin cytoskeleton [15]. Endogenous Kalirin-
9 is localized to neurites and growth cones, and expression
of exogenous Kalirin-9 induces longer neurites and altered
neuronal morphology in cultured cortical neurons [16]. The
functions of Kalirin-9 and Kalirin-12 in neurons remain
to be elucidated. The ΔKalirin-7 (also referred as Kalirin-
5) isoform is generated using a diﬀerent promoter, and
translation initiation begins at the start of spectrin-like
repeat 5, producing an isoform with only 5 spectrin-like
repeats. Overexpression of ΔKalirin-7 results in an increase
in spine size, but not spine density, in cultured cortical
neurons [17]. Duet, an isoform of Kalirin that begins just
before the second GEF domain and continues through the
unique C-terminal of Kalirin-12, uses a third promoter [7].
Duet was discovered as a protein homologous to the catalytic
domain of death associated protein kinase and is localized
to actin-associated cytoskeletal elements, suggesting the
involvement of Duet in cytoskeleton-dependent functions
[18].
3. TissueExpression
Kalirin expression is detectable in a wide array of adult
tissues including neurons, endocrine cells, liver, muscle, and
heart [2, 20, 21]. In addition, developmentally regulated,
tissue speciﬁc-Kalirin isoform expression is evident. Kalirin-
9 and -12 are highly expressed in neuronal tissue during
embryonic development, while in the adult brain expression
of each is drastically decreased; a concomitant increase in
Kalirin-7 expression occurs [8, 20, 22]. Kalirin-7 expression
is largely limited to neurons of the central nervous system;
i t sl e v e l sa r ee x t r e m e l yl o wa tb i r t h( p o s t n a t a ld a y s1 –
7) and begin to increase markedly at postnatal day 14,
which coincides with the onset of maximum synaptogenesis
[22, 23].
4. Kalirin-7Is the MajorKalirin
Isoform in Adult Brain
Kalirin-7 is the most abundant Kalirin isoform in the
adult rodent brain and is exclusively localized to the
postsynaptic side of excitatory synapses [19, 22, 39, 40].
Kalirin-7 is a multifaceted molecule containing domains that
interact with a wide array of molecular machinery. The
Sec14p domain located at the N-terminus interacts with
phosphatidylinositol-3-phosphate and plays a key role in
Kalirin-7-mediated spine morphogenesis (Ma et al., unpub-
lished). The C-terminus of Kalirin-7 contains a unique PDZ-
binding motif through which Kalirin-7 interacts with PDZ-
domain-containing proteins including PSD-95, AF-6, and
spinophilin [39]. Binding of the NMDA receptor subunit
NR2B to the PH domain of Kalirin-7 is important for
normal synaptic plasticity [41]. The spectrin-like domains
of Kalirin-7 through which it interacts with DISC1, iNOS,
PAM, HAP1, and Arf6 play a key role in Kalirin-7-induced
synapse formation (Ma et al., unpublished). The nucleotide
sequences of human Kalirin-7 (Duo) and rat Kalirin-7 are
91% identical, and their amino acid sequences are 98%
identical; human Kalirin-7 contains a 27-nucleotide insert
not found in rat Kalirin-7, located at the end of the region
encoding the seventh spectrin repeat [8, 12].
5. Kalirin-7ContainsMultiple
Phosphorylation Sites
Phosphorylation of Kalirin-7 has recently been shown to
be a pivotal mechanism mediating Kalirin-7-induced spine
formation and synaptic plasticity [42–44]. Puriﬁed PKA,
PKC, CaMKII, Cdk5, and Fyn each phosphorylate puriﬁed
Kalirin-7 [45]. Kalirin-7 is extensively phosphorylated in
vivo. The phosphorylation sites identiﬁed in vitro using
puriﬁed CaMKII, PKA, PKC, or CKII, identiﬁed only 5
of the 22 sites that undergo phosphorylation in cells or
tissue. These ﬁndings emphasize a critical role for additional
protein kinases and the importance of cellular localization
in the phosphorylation of Kalirin-7 [45]. Densely distributedNeural Plasticity 3
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Figure 2: Kalirin-12, not Kalirin-7, is localized to the growth cone of hippocampal neurons. Primary cultures of hippocampal neurons
prepared at embryonic day 20 (E20) were transfected with a vector encoding GFP on the day of culture preparation as described [19].
On day 3 after transfection, cultures were ﬁxed for staining of ﬁlamentous actin with Alexa Fluor 633 Phalloidin (Life Technologies) and
endogenous Kalirin-7 or Kalirin-12 with isoform-speciﬁc rabbit antibodies. Rabbit antibodies were visualized using Cy3 donkey anti-rabbit
IgG (The Jackson Laboratory). Images were collected with a Zeiss confocal microscope LSM510.
phosphorylation sites have been identiﬁed in the spectrin-
like repeat region, many lying on the fourth and ﬁfth
repeats. Their phosphorylation state could inﬂuence on a
wide array of protein-protein interactions that involve this
region. Since the ﬁrst four spectrin-like repeats are absent
in ΔKalirin-7 (Figure 1), the phosphorylation sites in the
missingregioncouldplayakeyroleinthediﬀerencesinspine
size and density associated with expression of full length
Kalirin-7 versus ΔKalirin-7. Overexpression of exogenous
Kalirin-7 results in an increase in both spine density and
spine size while overexpression of ΔKalirin-7 only increases
spine size without altering spine density [17]. Although
phosphorylation sites that regulate GEF activity as assessed
in intact cells have been identiﬁed, a relationship between
phosphorylation state and GEF activity has not yet been
demonstrated using puriﬁed proteins.
6.Kalirin-7PlaysaKeyRole in
Spine/SynapseFormationIn Vitro
Kalirin-7 expression islimitedtoneurons intheCNS[22,30,
46]. Immunostaining in cultured hippocampal and cortical
neurons demonstrates that Kalirin-7 clusters are apposed
to glutamate-transporter-1-(Vglut1-) positive clusters, a
marker for excitatory presynaptic terminals [19, 47, 48].
When cultured neurons are ﬁxed with cold methanol, it
can be seen that the Kalirin-7 positive clusters consistently
overlapclusterspositiveforPSD95,NMDAreceptorsubunits
NR1 and NR2B, or AMPA receptor subunits GluR1 and
GluR2;overlapisapparentinbothdendriticspinesandinthe
dendriticshaft[19,40].Incontrast,Kalirin-7clustersneither
align with GAD65-positive clusters, a marker for inhibitory
presynaptic terminals, nor with GABAA receptor positive
clusters, a marker for inhibitory postsynaptic endings [19].
These ﬁndings lead to the conclusion that Kalirin-7 is
localizedalmostentirelytopostsynapticexcitatoryterminals.
Regulation of Kalirin-7 expression by synaptic activity in
hippocampal neurons suggests that Kalirin-7 plays a pivotal
role in the regulation of excitatory synapse formation and
signaling [40, 42]. Overexpression of Kalirin-7 causes an
increase in dendritic spine density, spine size, and synapse
number,whilereductionofendogenousKalirin-7levelsleads
to a reduction in spine density, spine size, and synapse
number in cultured hippocampal and cortical neurons
[19, 22, 39]( Figure 3). Interestingly, overexpression of
Kalirin-7inducesspineformationinspine-freehippocampal
interneurons [19]a n dar e c e n ts t u d yr e p o r t sa ni m p o r t a n t
role of Kalirin-7 in regulating dendrite growth in cortical
interneurons [44]. A delicate balance between synaptic
excitation and inhibition is critical for maintaining normal
circuits in the CNS, and interneurons play an essential role
in regulating local circuit excitability [49]. Understanding
Kalirin-7 function in interneurons may increase our under-
standing of neurological diseases such as epilepsy, bipolar
disorder, schizophrenia, autism, and Alzheimer’s Disease,
which are related to disruption of GABAergic interneuron
development [50–53].
7.Kalirin-7PlaysaKeyRolein
Spine/SynapseFormation In Vivo
Two Kalrn knockoutmousemodelshavebeendeveloped:the
Kalirin-7 knockout mouse (Kalirin-7KO)[ 54] and the GEF1
Kalirin knockout mouse (KalirinGEF1−KO)[ 55]. Kalirin-7KO
mice, in which the terminal exon unique to Kalirin-7 was
deleted, grow and reproduce normally. Hippocampal CA14 Neural Plasticity
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Figure 3: Expression of Kalirin-7 shRNA causes a reduction in spine density and spine size in cultured hippocampal neurons. Cultured
hippocampal neurons prepared at E20 were transfected with vector encoding a membrane-tethered version of GFP (pmGFP) alone [(a),
spine density 8.9 ± 0.8/10μm], pmGFP plus a scrambled shRNA [(b), spine density 9.2 ± 0.9/10μm], or pmGFP plus pSIREN-Kalirin-7
shRNA [(c), spine density 5.2 ± 0.6/10μm] on the day of culture preparation. The speciﬁcity of pSIREN-Kalirin-7 shRNA was determined
previously [19]. DsRed marks transfected neurons expressing the shRNA. Images were collected on day 20 with an LSM510 confocal
microscope. Expression of Kalirin-7 shRNA, not scrambled shRNA, caused a 80% decrease in Kalirin-7 staining (not shown). Spine density
was determined using Metamorph (Molecular Devices, Downington, PA) as described [54]. Scale bar = 5μm.
pyramidal neurons of Kalirin-7KO mice show a 15% decrease
in spine density and deﬁcits in long-term potentiation
(LTP). Morphological alterations in Kalirin-7KO mice are
accompanied by behavioral alterations including decreased
anxiety-like behavior in the elevated zero maze and impaired
acquisition of a passive avoidance task. Kalirin-7KO mice
exhibitnormalbehaviorintheopenﬁeld,objectrecognition,
and radial arm maze tasks [54]. PSDs puriﬁed from the
cortices of Kalirin-7KO mice show a deﬁcit in Cdk5, a kinase
known to phosphorylate Kalirin-7 and play an essential
role in Kalirin-7-mediated spine formation and synaptic
function[43,54,56].Furthermore,NR2Blevelsaremodestly
decreased in PSD preparations from the cortices of Kalirin-
7KO animals [54]. This decrease is accompanied by decreased
levels of NR2B-dependent NMDA receptor currents in
cortical pyramidal neurons [41]. NR2B plays a critical role in
LTP induction, dendritic spine formation, diﬀerent forms of
synapticplasticity,learning,andmemory[57–60].Decreased
NR2B levels may partially contribute to decreased spine
density and the deﬁcit in LTP induction observed in Kalirin-
7KO mice. Importantly, expression of exogenous Kalirin-
7 in cultured Kalirin-7KO neurons rescues decreased spine
density. These ﬁndings show that Kalirin-7 plays an essential
role in synaptic structure and function.
The KalirinGEF1−KO mice were generated by replacing
exons27-28intheﬁrstGEFdomainbyaneomycinresistance
cassette, thus eliminating production of the major Kalirin
isoforms; in addition to Kalirin-7, these mice are unable
to produce Kalirin-9 and Kalirin-12 [55]. KalirinGEF1−KO
mice show signiﬁcant morphological deﬁcits including
reduced size of both cortex and decreased spine density
in pyramidal neurons of the cortex [55]. Interestingly, in
KalirinGEF1−KO mice the hippocampus is reduced in size
but spine density in hippocampal neurons is normal. This
reduction in hippocampal size in KalirinGEF1−KO mice results
from neuronal loss since Kalirin is exclusively expressed in
pyramidal neurons, granule cells of the dentate gyrus, and
interneurons scattered throughout the hippocampus [19, 22,
46, 54]. Both Kalirin-7KO and KalirinGEF1−KO mice show
impaired hippocampal LTP induction, impaired contextual
fear conditioning, and reduced spine density in cultured
cortical neurons and normal long-term memory [54, 61].
KalirinGEF1−KO mice show deﬁcits in working memory and
an intact reference memory. However, Kalirin-7KO and
KalirinGEF1−KO mice exhibit distinct diﬀerences in their
behavioral phenotype. KalirinGEF1−KO mice show very high
locomotor activity in the open ﬁeld and a deﬁcit in spatial
memory, which are not aﬀected in Kalirin-7KO mice [54, 55].
FurthercomparisonsofthephenotypesoftheKalirinGEF1−KO
and Kalirin-7KO mice are needed, along with the generation
of additional Kalrn knockout mouse models generated using
diﬀerent knockout strategies.
8. Kalirin-7Is ImplicatedinCocaineAddiction
Cocaine addiction is a chronic relapsing neurological dis-
order associated with severe medical and psychosocial
complications [62–66]. The long-lasting nature of cocaine
addiction leads to relapse and makes it especially diﬃcult
to treat [21]. Repeated cocaine treatments increase dendritic
spine density/spine head size and neurite complexity in
the brain’s reward circuitry such as the medium spiny
neurons(MSNs)ofthenucleusaccumbens(NAc).OurstudyNeural Plasticity 5
Table 1: Kalirin and human diseases.
Kalirin isoform Disease Physiological relevance References
Kalirin-7 (Duo) Schizophrenia Decreased spine density, decreased Kalirin-7
mRNA levels in the prefrontal cortex [24]
Kalirin (unknown isoforms) Schizophrenia Kalirin mRNA increases 2-fold in the
prefrontal cortex [25]
Kalirin-7 Schizophrenia DISC1 regulates spine formation via Kal7-Rac1 [10]
Kalirin Schizophrenia Kalirin is a risk factor for schizophrenia [26]
Kalirin-7 Alzheimer’s Disease Decreased levels of Kalirin-7 mRNA and
protein in hippocampus [27, 28]
Kalirin (unknown isoforms) Animal model of depression
Decreased Kalirin expression in the prefrontal
cortex and hippocampus. ECT increases
Kalirin expression in hippocampus
[29, 30]
Kalirin-7 Animal model of depression Decreased Kalirin-7 expression in
hippocampus [31]
Kalirin (unknown isoforms) Animal model of epilepsy Decreased Kalirin expression in hippocampus [32]
Kalirin (unknown isoforms) ADHD Unknown [33]
Kalirin (unknown isoforms) Stroke Unknown [34, 35]
Kalirin (unknown isoforms) Coronary Heart disease Unknown [36]
Kalirin (unknown isoforms) Huntington’s disease Spectrin-like domains of Kalirin interact with
HAP1 [12]
Kalirin-7 Animal model of cocaine
addiction
An essential determinant of dendritic spine
formation following cocaine treatment [37, 38]
shows that Kalirin-7 is an essential determinant of dendritic
spine formation following cocaine treatment [38]. Kalirin-
7 is expressed in the MSNs of the NAc, a key area in
the brain involved in drug addiction and reward pathways
[37]. Chronic cocaine treatment of wild-type mice results
in an increase in Kalirin-7 expression in the NAc which is
accompanied by an increase in spine density in the MSNs of
NAc core [37,67].Thiscocaine-inducedincreaseindendritic
spinedensityintheNAcMSNsinwild-typemiceisabolished
in Kalirin-7KO mice. Both wild-type and Kalirin-7KO mice
have identical spine densities in the MSNs of the NAc
prior to cocaine treatment. These morphological changes
could underlie the behavioral variations seen in these mice
following cocaine treatment. Chronic cocaine treatment
leads to increased locomotor sensitization in Kalirin-7KO
mice compared to wild-type controls [38]. These data
suggest Kalirin-7 plays an important role in the mechanism
of cocaine addiction, which needs to be addressed in the
future.
9.KalirinIsImplicatedinHumanDiseases
Altered Kalirin expression has been reported in several
neuropsychiatric,neurologicalandcardiovasculardiseasesas
well as animal models of depression, epilepsy and cocaine
addiction (Table 1). Genetic analyses have identiﬁed KALRN
as a major risk factor in stroke and early onset of coronary
artery disease [34–36]. Similarly in schizophrenia, decreased
dendritic spine density in the prefrontal cortex is reported
to correlate with decreased Kalirin mRNA levels [24]. A
rare missense mutation in the KALRN gene has been shown
to be a genetic risk factor for schizophrenia [26]. The
spectrin-like repeat region of Kalirin has also been shown to
interact with DISC1, a genetic risk factor for schizophrenia
which plays an important role in activity-dependent spine
elongation by promoting Kalirin-7/Rac-1 interactions [10,
24,68,69].Attention-deﬁcit/hyperactivitydisorder(ADHD)
is the most common neurobehavioral disorder and the
underlying molecular mechanisms of ADHD are largely
unknown. Animal models of ADHD are associated with
spine loss in striatal MSNs [70] and functional impairments
in glutamatergic synaptic transmission in the hippocampus
[71]. A genomewide association study of ADHD patients
has also implicated alterations in Kalirin expression in
ADHD [33]. Dendritic pathology and decreased dendritic
spine density are prominent phenomena in early cases of
Alzheimer’s Disease, which correlate signiﬁcantly with the
progressive decline of mental faculties [72–75]. Alzheimer’s
Disease patients also show a signiﬁcant decrease in Kalirin
mRNA and protein expression in the hippocampus without
signiﬁcant changes in other brain regions [28]. This decrease
in Kalirin expression has been associated with increased
iNOS activity both in hippocampus from Alzheimer’s
patientsandincultur edne ur oblast o mac ells[27].Thesedata
lead to the hypothesis that lack of Kalirin is associated with
the dendritic alterations and substantial decrease in spine
density observed in Alzheimer’s Disease.
The cause underlying major depression and the neurobi-
ological basis of antidepressant therapy are not clear. Altered
synaptic plasticity may play a key role in the pathogenesis6 Neural Plasticity
and treatment of depression [76]. Major depression is
associated with spine reductions in the hippocampus [77].
Kalirin expression and spine density in the hippocampus are
decreased in the animal models of depression [29, 31, 78].
Kalirin levels and spine density in the hippocampal CA1
pyramidal neurons increase after repeated electroconvulsive
treatment (ECT) [30, 79], one of the most eﬀective therapies
for depression [80, 81]. These observations suggest a role
for Kalirin in the development of depression. In epileptic
patients and in experimental models of epilepsy, there is
a marked spine loss, abnormal spine shape, and alteration
in dendritic morphology in hippocampal CA1 pyramidal
neurons [82, 83]. Animal models of epilepsy show a marked
increase in Kalirin expression in the hippocampus [32],
suggesting a role for Kalirin in the neuropathology of human
epilepsy. Kalirin interacts with Huntingtin-associated pro-
tein 1 (HAP1) [12] and HAP1 dysfunction could contribute
to the selective neuropathology in Huntingtin’s disease [84].
Huntingtin’s disease is characterized by loss of medium-
sized spiny neurons in the striatum [85], alterations in
spine density, and abnormalities in the size and shape of
dendritic spines in striatal MSNs [86–88]. Overexpression of
Kalirin-7 caused an increase in spine density while reduced
expression of Kalirin-7 resulted in loss of dendritic spines
and a decrease in dendritic complexity in the MSNs of
striatal slice cultures which mimic in vivo conditions (Ma
et al., unpublished). These data raise the possibility that
Kalirin-7 may play a role in the neuropathology of Hunt-
ington’s disease [87]. Finally, Kalirn-7 plays an important
role in estrogen-mediated spine/synapse formation in the
hippocampus [31, 40]. Regulation of Kalirin-7 by estrogen
suggests a role for Kalirin in ovarian hormone-associated
cognitive function and menopause-associated disorders [89–
91]. Taken together, altered dendritic spine morphology
and spine density remain the hallmarks of many human
neurological and psychiatric disorders. There is a correlation
between the levels of Kalirin expression and the pathology
of dendritic spines in some psychiatric and neurological
disorders. It is important to understand whether Kalirin is a
trigger or one of many factors mediating the dendritic spine
pathologyofthesediseases,whichmayberescuedbyaltering
Kalirin expression/function or targeting downstream signals
of Kalirin.
10. Conclusion/FutureStudies
Kalirin-7, the major isoform of Kalirin in the adult brain,
plays a critical role in spine formation/synaptic plasticity.
Estrogen-mediatedspineformationinhippocampalneurons
and cocaine-induced increases in spine density in striatal
MSNs require Kalirin-7. Kalirin has also been implicated
in many neuropsychiatric and neurological diseases. Future
studies will focus on investigating the underlying molecular
mechanismsofKalirin-7-mediated spineformation/synaptic
plasticity and its role in neuropsychiatric and neurological
diseases.
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